intoxicant.wiki2catechol4school
Compound

Remoxipride

Also called Romoxipride

Original Wikipedia articleen.wikipedia.org/wiki/Remoxipride revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Overview

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993. Remoxipride acts as a selective D₂ and D₃ receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.[1][2] WP

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. There was some interest in its use in the treatment of treatment-resistant schizophrenia.[3][4][5] WP

Chemistry

Formula
C16H23BrN2O3 PC
CAS number
80125-14-0 PC
Molar mass (g/mol)
371.27 PC
IUPAC name (computed by PubChem)
3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide PC
SMILES
CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC PC
InChIKey
GUJRSXAPGDDABA-NSHDSACASA-N PC
PubChem CID
54477

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Other Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A. Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. 2007
  2. Journal / agency Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica. Supplementum. 1990. doi:10.1111/j.1600-0447.1990.tb05282.x · PMID 1978484
  3. Journal / agency Alexander MS, Chakravarti SK, Sundararajan K, Mullin JM, Shaw SH, Blomqvist M, Lockett CM. Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia. Journal of Psychopharmacology. January 1993. doi:10.1177/026988119300700307 · PMID 22290842
  4. Journal / agency Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R. Remoxipride therapy in treatment resistant schizophrenia. Schizophrenia Research. April 1993. doi:10.1016/0920-9964(93)90521-J
  5. Journal / agency Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R. Remoxipride therapy in poorly responsive schizophrenics. Schizophrenia Research. April 1993. doi:10.1016/0920-9964(91)90208-9

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.